2022年ACR/EULAR抗中性粒细胞胞质抗体相关血管炎分类标准在儿童患者中表现良好:ARChiVe研究
该研究评估2022年ACR/EULAR分类标准在574例儿童慢性小至中等血管炎患者中的表现,并与儿童版EMA算法(含Ankara GPA标准)比较。结果显示ACR/EULAR标准分类出更多MPA患者、更少GPA与MPA重叠,GPA敏感性相当而特异性更优,支持在儿科GPA中优先使用ACR/EULAR标准。
要点
- 2022 ACR/EULAR标准在儿童AAV中分类效能不劣于既往儿科标准。
- ACR/EULAR标准首次提供明确的MPA分类标准。
- GPA与MPA标准能相互区分,临床特征频率差异更多。
核心结论
- 2022 ACR/EULAR AAV分类标准在儿童中表现至少与既往儿科标准相当,并首次提供MPA分类标准,支持优先用于儿科GPA。
研究设计与样本
- 基于ARChiVe注册的574例经医生诊断的儿童慢性小至中等血管炎患者队列,计算应用ACR/EULAR AAV标准与儿童版EMA算法(含Ankara GPA标准)进行分类。
主要发现
- ACR/EULAR标准较Ped-EMA算法分类出更多GPA或MPA患者(396例 vs 360例),更少GPA(261例 vs 288例),更多MPA(135例 vs 72例)。
- ACR/EULAR标准下GPA与MPA重叠分类比例为12%,低于Ped-EMA算法的28%。
- ACR/EULAR标准下GPA与MPA在PVAS定义临床特征上的差异数量为14项,多于Ped-EMA算法的10项。
- 以医生诊断对照,ACR/EULAR与Ankara标准诊断GPA的敏感性分别为74.5%与72.1%,特异性分别为93.9%与79.9%。
关键数值与推荐
- GPA敏感性:ACR/EULAR 74.5%,Ankara 72.1%;特异性:ACR/EULAR 93.9%,Ankara 79.9%。
- 分类为GPA或MPA的总例数:ACR/EULAR 396例,Ped-EMA 360例;GPA:261例 vs 288例;MPA:135例 vs 72例。
- GPA与MPA重叠分类比例:ACR/EULAR 12%,Ped-EMA 28%。
临床怎么用
- 在儿科AAV分类中可优先使用2022 ACR/EULAR标准,尤其GPA特异性优于Ankara标准。
- ACR/EULAR标准提供了明确的MPA分类条目,有助于儿童MPA的识别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the 2022 American College of Rheumatology (ACR)/EULAR classification criteria for antineutrophil cytoplasmic antibody-associated vasculitis (AAV) in children with chronic small-to-medium vessel vasculitis. METHODS: A cohort of 574 patients, identified by physician's diagnosis (MD-diagnosis) in A Registry of Childhood Vasculitis, was classified by computation of registry data as having granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), or eosinophilic GPA after applying (1) ACR/EULAR AAV criteria and (2) pediatric-adapted European Medicines Agency (Ped-EMA) classification algorithm (incorporating Ankara GPA criteria). Venn diagrams compared the resulting GPA and MPA cohorts with MD-diagnosis. Sensitivity and specificity of criteria for GPA were evaluated against MD-diagnosis. Fisher exact test evaluated differences in the frequencies of individual clinical features in GPA versus MPA. RESULTS: Comparing ACR/EULAR criteria against the Ped-EMA algorithm for classifying AAV, more patients were classified as GPA or MPA (n = 396 vs 360, respectively), fewer had GPA (n = 261 vs 288, respectively), more had MPA (n = 135 vs 72, respectively), and fewer GPA cases coclassified as MPA (12% vs 28%, respectively); there were more differences between GPA and MPA in Pediatric Vasculitis Activity Score-defined clinical features (n = 14 vs 10, respectively). When classifying GPA by ACR/EULAR or Ankara criteria, sensitivity (74.5% vs 72.1%, respectively) was comparable, and specificity for ACR/EULAR criteria (93.9% vs 79.9%, respectively) was improved. CONCLUSION: The 2022 ACR/EULAR classification criteria for AAV perform at least as well as previous pediatric criteria and provide categorical MPA criteria where none existed previously; the criteria for GPA and MPA now specifically differentiate each other, with more differences between them in the frequencies of clinical features. Our findings support the preferential use of ACR/EULAR over Ankara criteria for GPA in pediatrics.
引用
- Cabral DA, Bosman ES, McPhate N, et al. Effective Performance of the 2022 American College of Rheumatology/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Pediatric Patients: An ARChiVe Study. Arthritis Rheumatol. 2026. PMID: 41958151. doi:10.1002/art.70172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。